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We describe the prevalence of stage III and IV chronic kidney
disease in Thailand from a representative sample of
individuals aged 35 years and above using a stratified,
multistage, cluster-sampling method. Population estimates
were calculated by applying sampling weights from the 2000
Thai census. Glomerular filtration rates were estimated from
serum creatinine using the Cockroft–Gault and the simplified
Modification of Diet in Renal Disease (MDRD) formulae. The
prevalence of stage III disease among individuals aged 35
years and above was estimated to be about 20% using the
Cockroft–Gault formula and about 13% from the MDRD
formula. Stage IV disease was present in about 0.9 and 0.6%
of this population using the respective formulae. The highest
prevalence rates were observed in less well-developed rural
areas and the lowest in developed urban areas. The
prevalence of chronic kidney disease was significantly higher
than that reported in individuals over 40 years old from the
United States for both stage III and IV disease and higher
than the reported incidence in Taiwan and Australia. This
high prevalence of chronic kidney disease in Thailand has
obvious implications for the health of its citizens and for the
allocation of health-care resources.
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The presence of chronic kidney disease (CKD) is associated
with an increased risk of a multitude of adverse health
outcomes, including end-stage kidney disease (ESKD) as well
as a substantial reduction in life expectancy.1,2 Therapeutic
strategies to reduce the risk of ESKD and other complications
in individuals with CKD are now available,3 so early
recognition and the institution of proven therapeutic
strategies are important.
Large population-representative surveys in the United
States and Australia have reported the prevalence of CKD in
these countries;4,5 however, much less information is
available on prevalence rates elsewhere and, in particular, in
developing regions.6 Given the limited ability to afford
dialysis and the rapidly increasing prevalence of conditions
such as diabetes and hypertension that may predispose to the
development of CKD, prevention strategies may be especially
important in developing regions.7
Thailand is a developing country in Asia with a
population of more than 60 million people. The InterASIA
study was designed and performed to estimate the prevalence
of a variety of diseases in China and Thailand. In this study,
we aim to estimate the prevalence of CKD among adults in
Thailand.
RESULTS
Overall
Of the 7909 Thai individuals aged 35 years and above
invited to participate in InterASIA, 5303 (67%) took part in
this study and creatinine measurements were available for
5146. The characteristics of the participants are shown in
Tables 1 and 2.
Using the Cockroft–Gault formula, stage III CKD was
estimated to be present in 20.1% (95% confidence interval
(CI): 16.1–24.1) of Thai individuals aged more than 35 years
and stage IV CKD in 0.94% (CI: 0.44–1.44%). This equates to
approximately 5.0 million (CI: 4.5–5.5 million) and 230 000
(CI: 110 000–350 000) individuals with stage III and IV CKD,
respectively.
When the simplified Modification of Diet in Renal Disease
(MDRD) formula was used, stage III CKD was present in
13.2% (CI: 10.6–15.8%) of the population and stage IV CKD
in 0.61% (CI: 0.29–0.93%), equating to approximately 3.3
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million (CI: 2.6–3.9 million) and 150 000 (CI:
70 000–230 000) individuals, respectively. The distribution
of kidney function overall and in major population
subgroups is shown in Table 3. A direct relationship was
observed between age and CKD prevalence.
Development status. The proportion of individuals with
CKD in population groups defined by their development
status is shown in Figure 1 and their characteristics in
Table 2. The prevalence of CKD was progressively higher
across non-slum urban, slum urban, developed rural,
developing rural, and undeveloped rural populations.
Participants in less developed regions tended to be smaller
and thinner but had higher serum creatinine levels (Table 2).
The prevalence of hypertension was lower in less developed
regions (P¼ 0.01), and a lower prevalence of diabetes was
observed than in more highly developed regions (P¼ 0.03).
The prevalence of CKD by development status was
assessed separately for individuals with and without diabetes
and hypertension (Figure 2). The prevalence of CKD
decreased with increasing development status in people with
and without hypertension and in those who did not have
diabetes. No clear relationship was observed between
development status and CKD prevalence for individuals with
diabetes.
Comparison to the United States, Australia, and Taiwan
The estimated prevalence rates of stage III and IV CKD in
age- and sex-stratified subgroups of the United States,
Taiwanese, and Australian populations have been published
recently.4,5,8 The creatinine measurements from the Inter-
ASIA study were standardized using a common laboratory
for the US data to allow direct comparison of results for these
Table 1 | Estimated mean levels and prevalence of participant characteristics overall and in rural compared to urban Thai
adults aged 35 years and older
Rural Urban P-value
Age (years) 50.8 (1.4) 50.2 (1.5) 0.82
Women (%) 51.3 (6.6) 53.1 (7.8) 0.88
Serum creatinine (mg per 100 ml) 1.001 (0.016) 0.986 (0.019) 0.67
Creatinine clearance (ml min1) 76.0 (1.6) 79.6 (1.7) 0.30
GFR (ml min1) 77.1 (1.0) 78.3 (1.0) 0.55
Hypertension (4140/90 mm Hg) 14.6 (1.0) 23.1 (1.1) o0.001
SBP (mm Hg) 119 (1.0) 122 (1.2) 0.06
DBP (mm Hg) 75 (0.5) 78 (0.8) o0.001
Current smoking (%) 26.8 (4.4) 20.8 (3.1) 0.32
Current alcohol consumption (%) 35.6 (3.7) 33.9 (3.2) 0.76
Diabetes (%) 8.5 (0.8) 11.9 (1.0) 0.02
Height (cm) 157.1 (0.6) 58.3 (0.8) 0.40
Weight (kg) 58.3 (0.6) 62.0 (0.8) 0.001
Body mass index (kg m2) 23.6 (0.2) 24.7 (0.2) o0.001
BSA, body surface area; DBP, diastolic blood pressure; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; SBP, systolic blood pressure.
Values are mean (s.e.) or percent (s.e.).
Weighted using sampling factors from the 2000 Thai National Census population. Creatinine clearance calculated using the Cockroft–Gault formula and adjusted for a BSA of
1.73, GFR calculated using the simplified MDRD formula.
P-values relate to comparisons between rural and urban populations.
Table 2 | Baseline characteristics of participants according to region
Urban Rural
Factor Non-slum Slum Developed Developing Undeveloped P-value
Age (years) 50.2 (1.7) 50.2 (2.0) 50.9 (1.9) 50.6 (2.4) 50.9 (3.9) 0.99
Women (%) 53.1 (8.4) 53.0 (10.2) 50.6 (9.0) 52.8 (12.0) 60.8 (18) 0.98
Weight (kg) 62.0 (0.9) 61.5 (0.8) 59.1 (0.8) 56.2 (0.8) 54.8 (2.4) o0.0001
Height (cm) 158.3 (1.0) 157.7 (1.2) 157.3 (1.1) 156.6 (1.2) 153.9 (1.7) 0.25
Body mass index (kg m2) 24.7 (0.2) 24.7 (0.3) 23.9 (0.3) 22.9 (0.3) 23.0 (0.9) o0.0001
Body surface area (m2) 1.65 (0.02) 1.63 (0.02) 1.60 (0.01) 1.56 (0.02) 1.53 (0.04) 0.004
Creatinine (mg per 100 ml) 0.99 (0.02) 0.99 (0.03) 0.99 (0.03) 1.02 (0.03) 1.05 (0.05) 0.76
CG CrCl 80 (3) 80 (2) 77 (3) 73 (3) 70 (5) 0.15
MDRD GFR 78 (1) 79 (2) 78 (2) 75 (2) 72 (3) 0.22
Diabetes (%) 12.2 (1.1) 14.2 (1.7) 9.9 (1.2) 7.0 (1.2) 5.1 (1.2) 0.03
Hypertension (%, 4140/90 mm Hg) 26.0 (2.5) 26.7 (3.0) 19.8 (2.7) 13.0 (2.3) 17.9 (5.7) 0.01
SBP (mm Hg) 121.9 (1.3) 121.6 (1.5) 119.3 (1.3) 116.7 (1.2) 118.0 (3.0) 0.026
DBP (mm Hg) 78.1 (0.8) 78.7 (0.8) 75.0 (0.7) 73.2 (0.5) 73.9 (1.3) o0.0001
BSA, body surface area; DBP, diastolic blood pressure; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; SBP, systolic blood pressure.
Values are mean (s.e.) or percent (s.e.).
Weighted using sampling factors from the 2000 Thai National Census population. Creatinine clearance calculated using the Cockroft–Gault formula and adjusted for a BSA of
1.73, GFR calculated using the simplified MDRD formula.
Diabetes defined as known diabetes or fasting plasma glucose 4126 mg per 100 ml.
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two countries.9 Among individuals aged more than 40 years
(Table 4), stage III CKD was twice as prevalent in Thailand
compared to the United States according to both the
Cockroft–Gault (25.5 vs 12.3%, Po0.001) and MDRD
formulae (16.3 vs 8.1%, Po0.001). Stage III CKD was also
substantially more prevalent in Thailand than in either
Taiwan or Australia in age- and gender-matched subgroups
(Tables 4 and 5).
Stage IV CKD was rare in individuals aged less than 60
years, so accurate prevalence rates could only be calculated
for individuals aged more than 60 years (Table 4). Once
again, stage IV CKD was more prevalent in Thailand than in
the United States with both the Cockroft–Gault (3.5 vs 1.8%,
Po0.001) and the MDRD formulae (2.1 vs 0.9%, P¼ 0.001).
A nonsignificant trend toward an increased prevalence of
stage IV CKD was also observed when Thailand was
compared to Australia (Table 5), and the difference was
statistically significant in men but not in women. Data on
stage IV CKD from Taiwan were not available.
The population prevalence of an increased serum
creatinine level (over 1.6 mg per 100 ml for males and
1.4 mg per 100 ml for females) by age group has been
reported separately from the National Health and Nutrition
Evaluation Survey (NHANES) data,10 and the comparative
prevalence rates from Thailand and Australia are shown in
Table 6. The prevalence of elevated creatinine was signifi-
cantly higher in Thailand than in Australia and tended to be
higher than that in the United States.
Table 3 | Distribution of CKD stages overall and within subgroups of the Thai population
GFR prevalence
Subgroup No. of participants % of Thai population 490 60–89 30–59 o30
Overall 5146 100 22.0 (1.5) 64.0 (1.4) 13.4 (1.3) 0.6 (0.2)
Gender
Men 2018 48.7 23.5 (2.0) 64.3 (1.6) 11.5 (1.5) 0.7 (0.3)
Women 3081 51.3 20.6 (2.2) 63.7 (2.1) 15.1 (2.1) 0.6 (0.2)
Location
Urban 3035 32.3 22.4 (1.9) 65.7 (1.3) 11.2 (1.4) 0.6 (0.2)
Rural 2064 67.7 21.8 (2.0) 63.2 (1.9) 14.4 (1.7) 0.7 (0.2)
Region
Bangkok 989 10.9 22.5 (3.5) 67.9 (2.3) 9.6 (2.7) 0.1 (0.1)
North 1015 22.1 25.4 (4.7) 59.7 (3.3) 13.6 (2.1) 1.5 (0.5)
Northeast 1072 28.9 18.1 (2.1) 64.9 (3.0) 16.4 (3.3) 0.5 (0.3)
Central 1033 25.2 23.6 (2.6) 62.7 (1.4) 13.3 (2.3) 0.4 (0.3)
South 990 12.9 21.7 (3.8) 68.6 (2.6) 9.4 (2.4) 0.3 (0.2)
Age (years)
35–44 1548 40.8 35.0 (2.5) 62.8 (2.4) 2.1 (0.5) 0.1 (0.1)
45–54 1360 26.6 21.4 (2.0) 70.3 (2.2) 8.2 (0.9) 0.1 (0.1)
55–64 1181 17.2 8.7 (1.2) 67.7 (2.3) 22.6 (2.3) 1.1 (0.4)
65+ 1057 15.4 3.5 (1.0) 52.1 (2.9) 41.8 (3.2) 2.6 (0.9)
Diabetes
No 4478 90.3 22.3 (1.6) 65.4 (1.4) 11.9 (1.2) 0.4 (0.1)
Yes 615 9.7 19.4 (3.3) 50.7 (3.3) 26.7 (2.8) 3.0 (1.4)
Hypertension
No 3783 78.8 24.3 (1.7) 64.8 (1.6) 10.4 (1.3) 0.5 (0.1)
Yes, no medication 873 14.6 17.0 (2.4) 63.8 (2.4) 18.2 (2.1) 1.0 (0.5)
Yes, medication 443 6.6 6.0 (2.5) 54.5 (3.8) 37.5 (3.7) 2.0 (1.0)
CKD, chronic kidney disease; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.
The simplified MDRD formula was used to estimate GFR.
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Figure 1 | Prevalence of moderate (30–59 ml min1) and severe
(o30 ml min1) CKD calculated using the Cockroft–Gault formula
according to region.
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DISCUSSION
This study describes a remarkably high prevalence of CKD
among individuals aged 35 years and above in Thailand. One
in five individuals in this age group was found to have stage
III or greater CKD, as defined by Kidney Disease Outcomes
Quality Initiative (KDOQI),11 when the Cockroft–Gault
formula was used, and more than one in eight when the
simplified MDRD formula was used. These figures do not
include earlier stages of CKD defined by the presence of
proteinuria, hematuria, or structural damage, as data on
these parameters were not collected in this survey. As such,
these figures underestimate the total prevalence of all stages
of CKD as defined by KDOQI in this Asian population.
Providing these estimates are accurate, the results have major
implications for the citizens of Thailand and the health
services responsible for their care.
The prevalence of CKD as defined by reductions in
glomerular filtration rate (GFR) was found to be much
higher in Thailand than that either in the United States or in
Australia. However, the difference is less marked when
compared with the prevalence of CKD in Taiwan. Consistent
with this, elevated serum creatinine concentrations were also
found to be substantially more prevalent in Thailand than in
the United States or Australia. Serum creatinine results were
standardized,9 adding to the validity of the findings.
Recent reports have found a high prevalence of CKD in
other Asian countries; however, the prevalence of CKD is
higher in Thailand than in mainland China12 and Taiwan.8
The prevalence of CKD in mainland China varied signifi-
cantly depending upon whether the Cockroft–Gault or
MDRD method was used. For MDRD, the prevalence of
stage III CKD was reported to be 2.53% compared to 13.2%
in Thailand, and for the Cockroft–Gault method it was 19.6%
compared to 20.1% in Thailand. The discrepancy between
the MDRD- and Cockroft–Gault-based results is several fold
greater in the mainland Chinese study than that reported in
any other study, and it has not been clearly explained. A non-
representative study from Okinawa in Japan13 has also
reported prevalence rates of 13% overall when the MDRD
formula is used.
The observed high prevalence of CKD in Thailand
suggests that the number of people with stage V CKD who
would potentially benefit from dialysis or transplantation
might also be substantially higher than in western countries.
The incidence of ESKD among universal health-care coverage
beneficiaries in Thailand has been estimated to be between
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Figure 2 | Prevalence of moderate (30–59 ml min1) and severe
(o30 ml min1) CKD calculated using the Cockroft–Gault formula
according to region broken down by (a) blood pressure levels
and (b) diabetes status.
Table 4 | Estimated prevalence of moderate (creatinine
clearance or GFR o60) and severe (creatinine clearance or
GFR o30) CKD in the Thai compared to the US populations
according to age subgroups
P-value
Age subgroup
(years) Thailand USA Taiwan USA Taiwan
Stage III CKD
Cockroft–Gault
40–59 8.1 (0.9) 0.8 (0.2) NA o0.001
60–69 57.3 (3.1) 10.1 (1.1) NA o0.001
470 84.4 (2.7) 46.1 (1.2) NA o0.001
All 25.5 (0.6) 12.3 (0.3) NA o0.001
MDRD
40–59 7.5 (0.8) 1.8 (0.3) 3.4 (2.0) o0.001 0.17
60–69 31.7 (2.2) 7.6 (0.9) 21.7 (3.4) o0.001 o0.012
470 47.1 (3.2) 25.9 (1.1) 31 (3.7) o0.001 o0.0014
Overall 16.3 (0.5) 8.1 (0.3) NA o0.001
Stage IV CKD
Cockroft–Gault
40–59 NA* NA* NA
60–69 2.6 (0.8) 0.4 (0.2) NA o0.001
470 4.9 (1.4) 3.1 (0.4) NA 0.014
All 460 3.5 (0.1) 1.8 (0.1) NA o0.001
MDRD
40–59 NA* NA* NA
60–69 2.6 (0.8) 0.5 (0.2) NA o0.001
470 1.2 (0.6) 1.3 (0.3) NA 0.88
All 460 2.1 (0.1) 0.9 (0.1) NA 0.001
BSA, body surface area; CKD, chronic kidney disease; GFR, glomerular filtration rate;
MDRD, Modification of Diet in Renal Disease; NA, not available.
Values are percent (s.e.).
Weighted using sampling factors from the 2000 Thai National Census population.
Creatinine clearance calculated using the Cockroft–Gault formula and adjusted for a
BSA of 1.73, GFR calculated using the simplified MDRD formula.
*The number of observations available in these categories was too few to allow a
reliable estimate of prevalence.
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101 and 304 per million population (p.m.p.) and although
this range is quite broad, it is comparable to registry-based
data from Australia (90–100 p.m.p.14), Europe
(85–160 p.m.p.15), and the United States (336 p.m.p.16). The
prevalence of CKD in Taiwan has been reported to be higher
than that in the United States, and this country has the
highest rates of ESKD in the world.8 Since many individuals
in Thailand have limited access to dialysis due to a
combination of equipment, personnel, and financial resource
limitations,17,18 these findings suggest that there might be a
large gap between need for and provision of renal replace-
ment therapy (RRT) services.
The magnitude of the difference in the observed
prevalence of CKD between Thailand and previously
reported rates from the United States and Australia is
surprising. These findings raise the possibility of a large
looming burden of individuals needing renal replacement
therapy in Thailand over coming years and have profound
public health implications. Many of the countries have
limited health resources and are not currently able to provide
dialysis therapy or transplantation for the majority of
individuals with ESKD who may benefit from it.17,18 Thus,
any increase in the prevalence of stage V CKD could rapidly
translate into increased mortality and morbidity. The
findings of this study may offer a potential window of
opportunity for the use of therapeutic interventions known
to reduce the rate of progression of CKD and therefore the
incidence of ESKD and related diseases.
These important findings raise questions about the
methods used to measure and define kidney function and
CKD. This study was carefully performed, with a high
participation rate among invited individuals, careful collec-
tion of data, as well as appropriate collection, storage, and
transport of blood samples. The serum creatinine measure-
ments were all performed in a central standardized laboratory
and were subsequently standardized in the National Institutes
of Health (NIH) core laboratory to facilitate comparisons to
NHANES data. Calculations of kidney function were under-
taken using the most commonly used methods in clinical
practice. As a result, it appears likely that the findings are real
and are not due to methodological problems.
It is possible that definitions of CKD based on calculations
using the Cockroft–Gault and MDRD formulae are not
reliable in Asian populations. This would not explain the
differences in the prevalence of increased creatinine but may
lead to the prevalence of CKD being overestimated in both
this study and reports from China,12 Taiwan,8 and Japan.13
The accuracy of these formulae in Asian populations has been
subject to little study and is therefore uncertain. One recent
study performed in Chinese patients with CKD suggests that
both formulae underestimate GFR in stage I CKD, and
overestimate GFR in stage IV and V CKD.19 In stage III CKD,
the MDRD formula tends to overestimate GFR, while the
Cockroft–Gault formula was shown to reflect GFR measured
by gold standard nuclear techniques.19 Of note, the
prevalence of stage III CKD in Thailand was higher when
estimated using the Cockroft–Gault formula (20.1%) than
the MDRD formula (13.2%). It is therefore possible that the
higher Cockroft–Gault-derived estimate of CKD prevalence
may be more accurate. A similar study directly comparing
estimated and measured GFR in a Thai population would be
an important means of validating our results.
A possible explanation for the high prevalence of CKD in
Thailand is suggested by the observed variation according to
the development status. It may have been expected that the
highest prevalence of CKD would be observed in urban areas
where the prevalence of diabetes and hypertension was
greatest (Table 2), as the prevalence of CKD was higher in
individuals with either hypertension or diabetes than those
without these conditions (Figure 2). The reverse pattern was
actually found (Figure 1), with an inverse relationship
between the level of development of each region and the
prevalence of CKD within it. Other factors such as endemic
infection, sanitation, and access to perinatal and general
health care may contribute to this observed difference.20,21
Table 5 | Estimated prevalence of stage III and IV CKD
(calculated using the Cockroft–Gault formula) in the Thai and
Australian populations according to gender and age
subgroups
Age subgroup (years) Thailand Australia P-value
Stage III CKD
Male
45–65 23.0 (3.0) 1.8 (0.4) o0.001
465 82.4 (3.3) 51.8 (2.4) o0.001
Female
45–65 13.3 (2.4) 3.2 (0.7) o0.001
465 74.5 (3.6) 57.2 (2.9) o0.001
Stage IV CKD
Male
45–65 0.4 (0.2) 0 0.005
465 7.2 (2.8) 1.5 (0.4) 0.004
Female
45–65 0.5 (0.2) NA NA
465 2.9 (1.1) 1.9 (0.6) 0.39
BSA, body surface area; CKD, chronic kidney disease; GFR, glomerular filtration rate;
MDRD, Modification of Diet in Renal Disease.
Values are percent (s.e.).
Weighted using sampling factors from the 2000 Thai National Census population.
Creatinine clearance calculated using the Cockroft–Gault formula and adjusted for a
BSA of 1.73, GFR calculated using the simplified MDRD formula.
Table 6 | Estimated prevalence of elevated creatinine (1.6 mg
per 100 ml or greater in men, 1.4 mg per 100 ml or greater in
women) in the Thai compared to the US and Australian
populations according to age strata
P-value
Age subgroup Thailand USA Australia USA Australia
40–59 1.6 (0.3) 1.3 (0.3) 0.13 (0.05) 0.48 o0.001
460 10.6 (0.6) 7.3 (1.4) 1.9 (0.3) 0.057 o0.001
Values are percent (s.e.).
Weighted using sampling factors from the 2000 Thai National Census population.
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This variation is clearly worthy of further study and more
detailed analyses are underway.
This study has some important limitations. GFR was
estimated using formulae rather than being directly mea-
sured, and it was based on a single measurement of serum
creatinine for each individual. It was restricted to individuals
aged 35 years and above; therefore, the prevalence of CKD in
younger individuals could not be estimated. Data regarding
urinary albumin and protein excretion were not collected, so
the prevalence of stage I and II CKD could not be estimated
in this population. Finally, the formulae used to estimate
GFR have not been validated in an Asian population, so it is
not possible to say with certainty that the prevalence of CKD
is truly as high as the results of this study suggest.
The strengths of this study are its careful design and
conduct, its excellent response rate, and the potential
significance of the high reported prevalence of CKD. These
important findings deserve further study, in particular,
further investigation into possible mechanisms. More in-
formation on the health implications of CKD in Thailand
and on the prevalence of CKD in other parts of the
developing world is urgently required.
MATERIALS AND METHODS
A detailed description of the InterASIA study methods and procedures
has been published elsewhere.7 In brief, rural regions in Thailand were
divided into developed, developing, and undeveloped areas, and urban
regions were divided into slum and non-slum areas. Classification of the
development status of urban and rural enumeration districts (EDs) is
based on comprehensive development criteria defined by the Depart-
ment of Community Development of the Thai Ministry of the Interior
(http://www.porchor.moi.go.th/N2C/N2c4.html). Within each of these, a
city block or village (in urban or rural areas, respectively) is made up of
an ED. Within each ED, and using local government registers of
households, the population aged 35 years and above was stratified into
eight demographic groups, defined by age (35–44, 45–54, 55–64, and
X65 years) and gender. Individuals were then sampled at random from
each demographic group with the goal of recruiting a similar number of
participants from each, but selecting no more than one individual from
any household. The study was approved by an institutional review board,
and all participants provided written informed consent.
Trained study staff administered a structured questionnaire,
performed a brief physical examination, and collected a fasting
blood sample from each participant. The questionnaire sought
information about basic sociodemographic variables, cardiovascular
risk factors, history of cardiovascular diseases, current treatments,
and behavioral characteristics. The physical examination included
three measurements of blood pressure and a standard anthropo-
metric assessment (height, weight, waist, and hip circumference).
Biochemistry
Biochemical analysis was performed on venous blood samples
obtained after an 8-h overnight fast. Samples were stored
immediately on ice, centrifuged, and separated on the day of
collection. Sera were subsequently frozen and transported on dry ice
to a central laboratory (Faculty of Medicine, Ramathibodi Hospital,
Bangkok), where they were stored at –70 1C until they were analyzed
using the Dimension RxLHM clinical chemistry system (Dade
Behring Inc., Newark, Delaware, USA).
To allow direct comparison to previously published data from
the third wave of the NHANES in the US population,4 serum
creatinine measurements were standardized against stored sera at
the NIH AASK core laboratory (Cleveland, OH, USA). A total of 200
serum samples across the range of observed results were sent to this
laboratory, and the serum creatinine levels were remeasured. A
regression formula was calculated for the two measurements, and
this was used to adjust the original InterASIA serum creatinine
measurements (adjusted creatinine¼ 1.0617measured creatinine,
R2¼ 0.98). This adjustment did not significantly affect the results of
the study.
Defining chronic kidney disease
The level of kidney function for each individual was estimated using
both the simplified MDRD and the Cockroft–Gault formulae. The
simplified MDRD formula is
GFR ¼186:3creatinine1:154age0:203 ð0:742 for womenÞ
ð1:21 for African AmericansÞ
where creatinine is in mg per 100 ml and age is in years.22
The Cockroft–Gault formula is
creatinine clearance ðCrClÞ ¼ ð140  ageÞ=creatinineweight=
72ð0:85 for womenÞ
where age is in years, serum creatinine in mg per 100 ml, and weight
in kg.23 The estimated creatinine clearance was then corrected for a
body surface area (BSA) of 1.73 m2 using the DuBois and DuBois
formula:24
BSA¼ 0.20247 height (m)0.725weight0.425
The National Kidney Foundation Kidney Disease Outcomes Quality
Initiative (KDOQI) definitions of moderate (stage III, GFR, or CrCl
30–59 ml min1) and severe (stage IV, CrCl, or GFR 15–29 ml min1)
CKD were used.11
Statistical methods
The STATA 8.0 statistical software package (StataCorp, College
Station, TX, USA) was used to estimate risk factor levels taking
appropriate account of the complex survey design (using the ‘svy’
command for all analyses) and using weights derived from the 2000
Thai National Census. Estimates of means and proportions (with
s.e. or CIs) were calculated for the overall population and for
population subgroups defined by a range of different characteristics
of interest. Comparison of risk factor levels between population
subgroups was performed using t-tests, analysis of variance
derived from linear regression models for continuous variables,
and w2 tests for categorical variables. Comparisons of results from
previous surveys done in other countries were performed using
published proportions, which were calculated taking population
weights into account. We derived weighted proportions within
Thailand, as described above, and compared them to the published
proportions from other countries using w2 tests to test for
differences.
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